Coverage spread: 2 sources — 2 international
Lean ratings via AllSides / Media Bias-Fact-Check. How this works.
What was announced
Johnson & Johnson (J&J) has proposed to pay up to $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talc-based baby powder and related products caused ovarian cancer. The offer, disclosed Monday, would see J&J pay up to $3 billion in 2026, with no further payments required before 2028. Erik Haas, the company’s vice president of litigation, described the allegations as “meritless” but said the settlement would allow the healthcare giant to “put this matter behind it” and refocus on developing medicines and devices.
The proposal is not final: it must first be accepted by law firms representing 95% of ovarian cancer claimants currently in state and federal courts. BBC reports the deal would cover roughly 76,000 cases, while Al Jazeera puts the figure at about 69,000 cases, which it says represents 99.75% of outstanding US talc-related claims. Lawyers representing plaintiffs have reportedly welcomed the settlement as a positive resolution after more than a decade of litigation.
Background of the litigation
Lawsuits against J&J over talc-based baby powder date back to at least 2009, with claimants and the families of deceased users alleging that talc was contaminated with asbestos — a known carcinogen — because talc is often mined from deposits located near asbestos seams. J&J has consistently denied these claims, maintaining that “studies show talc is safe, does not contain asbestos and does not cause cancer.”
Al Jazeera notes a key early milestone: in 2016, a US jury awarded $72 million to the family of a woman who died of ovarian cancer in what was the first such verdict against the company, though it was later overturned. Since then, numerous juries have ruled against J&J in similar cases, fueling the wave of litigation the new settlement aims to close out. Earlier this July, according to the BBC, a federal court sided with J&J by questioning whether individual plaintiffs could prove talc directly caused their cancer — a ruling the company’s litigation chief cited as evidence it would likely have prevailed in further court battles.
J&J had already moved away from the product at the center of the dispute: it stopped selling talc-based baby powder in the United States in 2020, switched its global baby powder line to a cornstarch-based formula in 2022, and ended talc-based sales worldwide by 2023, according to the two sources’ slightly differing timelines.
What the settlement does not cover
Both outlets note the deal is limited to the United States. J&J’s former consumer health division, Kenvue — spun off in 2022 and now owner of brands such as Band-Aid, Listerine and Calpol — retains liability for Johnson’s baby powder claims outside North America, per the BBC. Al Jazeera highlights that the settlement excludes the United Kingdom, where what it describes as the largest product liability case in British history is underway. Filed in October 2025 and covering more than 7,000 potential claimants, the UK case alleges J&J knew of talc’s cancer risks — including ovarian cancer and mesothelioma — but continued selling the product regardless; J&J denies this as well. That case is now before the UK High Court.
Where coverage differs
The BBC and Al Jazeera largely agree on the core facts — the $5.5 billion figure, J&J’s denial of wrongdoing, the payment schedule, and quotes from Erik Haas — but diverge in emphasis and some figures. The BBC focuses more on the corporate and legal mechanics of the deal, including the Kenvue spinoff’s separate liability and the recent federal court ruling favorable to J&J, framing the settlement partly as a strategic move by a company that believed it could keep winning in court. Al Jazeera places more emphasis on the global and scientific context, notably citing the World Health Organization’s 2024 classification of talc as “probably carcinogenic to humans” — a detail absent from the BBC account — and gives greater prominence to the ongoing UK lawsuit as an unresolved front in the broader talc controversy. The two outlets also cite slightly different case counts (76,000 versus 69,000) and percentages of plaintiff participation required, likely reflecting different snapshots of the same evolving negotiation.
Why it matters
The proposed settlement would mark one of the largest product liability resolutions in US corporate history and could close a legal saga stretching back over a decade, one that has repeatedly weighed on J&J’s finances and reputation. Yet its finalization hinges on near-unanimous buy-in from plaintiffs’ lawyers, and it leaves major legal exposure intact abroad — most notably in the UK, where a separate and substantial case questioning J&J’s knowledge of talc’s risks continues to unfold. The dispute also sits within a broader public health debate, underscored by the WHO’s classification of talc as a probable carcinogen, ensuring that questions about the mineral’s safety and its historic use in consumer products will likely persist even after the US lawsuits are resolved.
Sources
Featured photo by Odd Fellow on Unsplash